Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04029116
Recruitment Status : Recruiting
First Posted : July 23, 2019
Last Update Posted : September 25, 2020
Sponsor:
Information provided by (Responsible Party):
Scynexis, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).

Condition or disease Intervention/treatment Phase
Recurrent Vulvovaginal Candidiasis Drug: Fluconazole Tablet Drug: IBREXAFUNGERP Drug: Placebo oral tablet Phase 3

Detailed Description:

This study is a Phase 3, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with RVVC. The primary objective of the study is to evaluate the efficacy of oral ibrexafungerp in preventing recurrences of VVC in subjects with RVVC based on Clinical Success. Approximately 320 subjects are planned to be enrolled into the study. All subjects will receive treatment with oral fluconazole for their acute episode present at screening. Subjects who respond to fluconazole for their acute episode will be enrolled in the prevention of recurrence phase of the study and randomized to ibrexafungerp or placebo.

Subjects who fail treatment with fluconazole for their acute episode will be included in a nested open label Sub-Study, in which they will be offered one-day oral ibrexafungerp for their unresolved acute episode.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label (acute phase treatment) followed by Randomized, Double Blinded phase
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Actual Study Start Date : September 23, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Yeast Infections
Drug Information available for: Fluconazole

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ibrexafungerp
Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Ibrexafungerp 300 mg BID (one day) every 4 weeks for a total of 6 dosing days
 Drug: Fluconazole Tablet
150 mg every 72 hours for 3 doses

Drug: IBREXAFUNGERP
300 mg BID (one day) every 4 weeks for a total of 6 dosing days
Other Name: SCY-078
Placebo Comparator: Placebo
Oral Fluconazole 150 mg every 72 hours for 3 doses followed by Oral Placebo BID (one day) every 4 weeks for a total of 6 dosing days
 Drug: Fluconazole Tablet
150 mg every 72 hours for 3 doses

Drug: Placebo oral tablet
BID (one day) every 4 weeks for a total of 6 dosing days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Clinical Success [ Time Frame: Week 24 ]
    Efficacy as measured by the percentage of subjects with documented Clinical Success.


Secondary Outcome Measures :
  1. The percentage of subjects with no Mycologically Proven Recurrence [ Time Frame: Week 24 and Week 36 ]
    Efficacy as measured by the percentage of subjects with no Mycologically Proven Recurrence

  2. Safety and tolerability [ Time Frame: Week 24 ]
    Safety as measured by the number of subjects who discontinue due to treatment related adverse events.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Diagnosis of symptomatic VVC with microscopic examination with KOH positive for yeast and normal vaginal pH.
  • History of 3 or more episodes of VVC in the past 12 months.
  • Culture confirmation and resolution of the signs and symptoms of the initial VVC episode (with treatment).
  • Able to take oral tablets and capsules.

Key exclusion Criteria:

  • Vaginal conditions other than recurrent VVC that may interfere with the diagnosis or evaluation of response to therapy.
  • Recent use of systemic and/or topical vaginal antifungal products.
  • Pregnant.
  • History of major system organ disease.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04029116


Contacts
Layout table for location contacts
Contact: Philip Deane 201 688 2241 ext 2241 philip.deane@scynexis.com
Contact: Nkechi Azie, MD Nkechi.azie@scynexis.com

Locations
Show Show 26 study locations
Sponsors and Collaborators
Scynexis, Inc.
Investigators
Layout table for investigator information
Study Director: Nkechi Azie, MD Scynexis, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Scynexis, Inc.
ClinicalTrials.gov Identifier: NCT04029116    
Other Study ID Numbers: SCY-078-304
First Posted: July 23, 2019    Key Record Dates
Last Update Posted: September 25, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Scynexis, Inc.:
Recurrent yeast infection
Recurrent yeast vaginitis
Chronic yeast vaginitis
 Ibrexafungerp
SCY-078
RVVC
Additional relevant MeSH terms:
Layout table for MeSH terms
Candidiasis
Candidiasis, Vulvovaginal
Mycoses
Vulvovaginitis
Vaginitis
Vaginal Diseases
Vulvitis
Vulvar Diseases
Fluconazole
Antifungal Agents
Anti-Infective Agents
 14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors